Ruthenium−Ferrocene Bimetallic Agent
- Scientists from Agharkar Research Institute (ARI), Pune, have discovered a Ruthenium−Ferrocene bimetallic agent that shows a highly potent antitumor effect in platinum-resistant cancers.
- Platinum drugs are the frontline treatment option for many cancers. But their broad applicability is severely limited due to the fast development of resistance against these drugs.
- The new agent is the first rationally designed Ruthenium-Ferrocene bimetallic complex identified to date that possesses low toxicity but both potent antitumor as well as anti-angiogenic properties.
- The complex can inhibit primary tumor growth and metastasis as well as kill cancer cells ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
News Snippets
- 1 Regional Power Conference with North Eastern States
- 2 President Droupadi Murmu Visits Slovakia
- 3 Cabinet Committee on Security (CCS)
- 4 India VIX
- 5 SAARC Visa Exemption Scheme
- 6 DigiLocker
- 7 SEFCO-2025
- 8 Goods and Services Tax Appellate Tribunal (GSTAT)
- 9 Index of Industrial Production (IIP)
- 10 Tax Collected at Source
